| 1 | 150 mg double-blinded secukinumab | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 2 | 150 mg open-label secukinumab | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 3 | 300 mg double-blinded secukinumab | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 4 | Other: secukinumab | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 5 | SECUKINUMAB | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 8件:  13 13, 37, 41, 46, 107, 160, 269, 271 | 
| 6 | Secukinumab (150 mg) | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 7 | Secukinumab (75 mg) | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 8 | Secukinumab (AIN457) | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  46 46 | 
| 9 | Secukinumab (AIN457) 150 mg s.c. | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 10 | Secukinumab 150 mg (2 injections per dose | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  269 269 | 
| 11 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 12 | Secukinumab 150 mg/1 mL Solution for injection | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 2件:  37 37, 271 | 
| 13 | Secukinumab 150 milligram [Cosentyx] | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 14 | Secukinumab 150mg | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  37 37 | 
| 15 | Secukinumab 300 mg | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  41 41 | 
| 16 | Secukinumab 300 mg, s.c. | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  41 41 | 
| 17 | Secukinumab 300mg | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  37 37 | 
| 18 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  271 271 | 
| 19 | Secukinumab Injection | 1件:  Secukinumab Secukinumab | 1件:  D09967 
                
                    D09967
                
             (Name: Secukinumab) | 1件:  IL17A IL17A 💬 | 6件:  Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件:  160 160 |